GRI Bio Regains Conditional Compliance With Nasdaq Listing Requirements

The latest update is out from GRI Bio ( (GRI) ).

On January 15, 2026, GRI Bio, Inc. was notified by Nasdaq’s Listing Qualifications Staff that it had conditionally regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies with a market value under $35 million and annual net income under $500,000 to maintain at least $2.5 million in stockholders’ equity. The company had previously been found out of compliance based on its Form 10-Q for the quarter ended September 30, 2025, and while the current determination averts an immediate delisting, GRI Bio’s stock remains at risk of future delisting if it fails to maintain the required equity levels in subsequent filings.

The most recent analyst rating on (GRI) stock is a Hold with a $0.23 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.

Spark’s Take on GRI Stock

According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.

The score is held down primarily by weak financial performance (heavy losses and ongoing cash burn) and bearish technical trend/momentum. Valuation is constrained by unprofitable earnings and no dividend support. Offsetting these risks, recent corporate updates (positive Phase 2a data and new financing) provide incremental support but do not overcome the current financial and trend weakness.

To see Spark’s full report on GRI stock, click here.

More about GRI Bio

GRI Bio, Inc. is a company listed on the Nasdaq Capital Market. Its shares are subject to Nasdaq’s listing standards, including minimum stockholders’ equity requirements applicable to smaller-cap issuers with lower market value and net income.

Average Trading Volume: 2,103,367

Technical Sentiment Signal: Sell

Current Market Cap: $3.32M

For an in-depth examination of GRI stock, go to TipRanks’ Overview page.